Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses

Journal of Cutaneous Medicine and Surgery

Volumn 7, Issue 5, 2003, Pages 382-386

  Drosou, Anna ^a   Kirsner, Robert S ^a,b   Welsh, Esperanza ^a   Sullivan, Tory P ^a   Kerdel, Francisco A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CLOFAZIMINE; CYCLOSPORIN A; DAPSONE; ETRETIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONFUSION; CROHN DISEASE; DISCOID LUPUS ERYTHEMATOSUS; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIC FASCIITIS; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYDROTHERAPY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; INSOMNIA; MALE; NAUSEA; NECROBIOSIS LIPOIDICA; PANNICULITIS; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; STEROID THERAPY; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344629146     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-002-0134-1     Document Type: Review

References (37)

1. Braun J, Xiang J, Brandt J, et al. Treatment of spondyloarthropathies with antibodies against tumor necrosis factor alpha: first clinical and laboratory experiences. Ann Rheum Dis 2000; 59(Suppl I):i85-i89.
2. Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356 (9244):1821-1822.
3. Schwartz EM, Looney RJ, O'Keefe RJ. Anti-TNF alpha therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res 2000; 23:165-168.
4. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNFalpha antibody. Bone Marrow Transplant 2001; 281:47-49.
5. Couriel DR, Hicks K, Giralt S, et al. Role of tumor necrosis alpha inhibition with infliximab in cancer therapy and hematopoietic stem-cell transplantation. Curr Opin Oncol 2000; 126:582-587.
6. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357:1842-1847.
7. Ogilvie ALJ, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumor necrosis factor alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144:587-589.
8. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284:1546-1548.
9. Botros N, Pickover L, Das KM. Image of the month: Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology 2000; 118:654-809.
10. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behcôet's syndrome with tumor necrosis alpha blocking therapy. Ann Rheum Dis 2001; 60(6):637.
11. Robertson IP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology 2001; 40:473-474.
12. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 181:70.
13. Geyer AD, Anhalt GJ, Nossari HC. Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease. Arch Dermatol 2000; 136:459-460.
14. Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001; 71:38-42.
15. Sullivan T, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis supprativa, submitted for publication.
16. Geren SM, Kerdel FA, Falabella AF, et al. Infliximab: A treatment option for ulcerative pyoderma gangrenosum. Wounds 2003; in press.
17. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15):1098-1104.
18. Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, et al. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol 2001; 96(5):1665-1666.
19. Conaghan PG, Sommer S, McGonagle D, et al. The relationship between pityriasis rubra pilaris and inflammatory arthritis: case report and response of the arthritis to anti-tumor necrosis alpha immunotherapy. Arthritis Rheum 1999; 42(9):1998-2001.
20. Markham A, Lamb HM. Infliximab: A review of its use in the management of rheumatoid arthritis. Drugs 2000; 59:1342-1359.
21. Maini RN, St, Clair EW, Breedveld F, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999; 354:1932-1939.
22. AnonymousInfliximab, Mosby's GenRx, 11th ed.C.V. Mosby, Inc., St. Louis, MO 2001.
23. Papadakis KA, Targan SR. Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterology 2000; 119:1148-1157.
24. Dinarello CA. Proinflammatory cytokines. Chest 2000; 1182:503-509.
25. Schaible TF. Long term safety of infliximab. Can J Gastroenterol 2000; 14(Suppl C):29C-52C.
26. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to TNFalpha: findings in label and randomized placebo controlled trials. Arthritis Rheum 2000; 43(11):2383-2390.
27. Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Cur Opin Rheum 2000; 12:49-52.
28. Bell S, Kamm MA. Antibodies to tumor necrosis factor alpha as treatment for Crohn's disease. Lancet 2000; 355:858-860.
29. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91(11):988-998.
30. Furst DE, Breedveld FC, Burmester GR, et al. Updated consensus statement on tumor necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Ann Rheum Dis 2000; 59 Suppl 1:i1-i2.
31. Young V, Ho M, Vosper H, et al. Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology 2002; 41(8):869-875.
32. Hasegawa M, Fujimoto M, Kikuchi K, et al. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997; 24(4):663-665.
33. Espana A, Sanchez-Yus E, Serna MJ, et al. Chronic balanitis with palisading granuloma: an atypical genital localization of necrobiosis lipoidica responsive to pentoxifylline. Dermatology 1994; 188(3):222-225.
34. Noz KC, Korstanje MJ, Vermeer BJ. Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline. Clin Exp Dermatol 1994; 18(1):78-79.
35. Ordi-Ros J, Cortes F, Cucurull E, et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 2000; 27(6):1429-1433.
36. Werth VP, Zhang W, Dortzbach K, et al. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol 2000; 115(4):726-730.
37. Fautrel B, Foltz V, Frances C, et al. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent. Arthritis Rheum 2002; 46(5):1408-1409.